ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
December 10, 2019
6 min watch

Polatuzumab vedotin plus obinutuzumab, lenalidomide shows promise in R/R follicular lymphoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ORLANDO — Catherine Diefenbach, MD, director of the clinical lymphoma program and of hematology translational research, Perlmutter Cancer Center at NYU Langone Health, presented efficacy and safety data from a phase 1b/2 study of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma at ASH Annual Meeting & Exposition.

These data showed that this novel triplet combination is a highly active, safe and tolerable regimen for patients with heavily pretreated relapsed and refractory follicular lymphoma, according to Diefenbach.

“We had a complete response rate that ranged from 62% to 73%,” she said. “For patients who were not refractory to their most recent line of therapy, the [complete response] rate was actually an astonishing 86%, but even for patients who were refractory to chemotherapy, their complete response rate was 40%, which is extremely impressive for this patient population.”

Disclosures: Diefenbach reports research funding from Bristol-Myers Squibb, Denovo, Genentech, Incyte, LAM Therapeutics, MEI, Merck, Millennium/Takeda, Seattle Genetics and Trillium, as well as consulting for Bristol-Myers Squibb, Genentech, Merck and Seattle Genetics.